Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer

Summary

This is a prospective study on the prevention of Neratinib-related diarrhea in a Chinese population, exploring the best options for reducing the incidence of neratinib-related diarrhea through either pharmacologic intervention (prophylactic antidiarrheal therapy) or non-pharmacologic intervention (dose escalation program).

Timeline

Start

2022-01-01

Primary completion

2023-12-31

Completion

2024-12-31

Drugs

Indications